4 Healthcare Stock Stories for Monday Investment Wellness
Amgen Inc. (NASDAQ:AMGN): Closing price $111.93
On Monday, Amgen reported additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC, or IV melanoma versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Results of the study’s key secondary endpoints will be presented during a poster session at the 17th ECCO — 38th ESMO — 32nd ESTRO European Cancer Congress in Amsterdam.
New data presented include investigator assessments of response: the durable response rate stood at 19 percent with talimogene laherparepvec as compared with one percent for the GM-CSF arm, and the objective response rate was 31 percent versus six percent in the GM-CSF arm.